Skip to content
2000
image of Azole Antifungals Under Pressure: Therapeutic Challenges and Multifaceted Resistance Mechanisms

Abstract

Fungal infections have increased markedly in both incidence and severity over recent decades, driven in part by the emergence of novel pathogenic species harboring sophisticated resistance mechanisms against commonly used antifungal agents. This alarming trend is especially pronounced with azoles, which remain widely used in clinical settings due to their broad-spectrum activity and favorable oral bioavailability. Azoles exert their antifungal effect by inhibiting lanosterol 14α-demethylase, a key enzyme in the ergosterol biosynthesis pathway, thereby compromising the integrity, fluidity, and functionality of the fungal cell membrane. However, the escalating prevalence of multidrug-resistant fungal strains, particularly those resistant to azoles, has significantly complicated therapeutic strategies and represents a growing threat to global public health. This perspective explores the diverse and increasingly complex mechanisms of azole resistance in clinically relevant fungi, particularly species of and , highlighting the urgent need for enhanced surveillance, novel therapeutic approaches, and responsible antifungal stewardship.

© 2025 Bentham Science publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673413219250826055238
2025-09-02
2025-11-04

  • From This Site

    /content/journals/cmc/10.2174/0109298673413219250826055238
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Rayens E. Rayens M.K. Norris K.A. Demographic and socioeconomic factors associated with fungal infection risk, United States, 2019. Emerg. Infect. Dis. 2022 28 10 1955 1969 10.3201/eid2810.220391 36149028
    [Google Scholar]
  2. Suleyman G. Alangaden G.J. Nosocomial fungal infections: Epidemiology, infection control, and prevention. Infect. Dis. Clin. North Am. 2021 35 4 1027 1053 10.1016/j.idc.2021.08.002 34752219
    [Google Scholar]
  3. Garcia-Bustos V. Cabañero-Navalon M.D. Ruiz-Gaitán A. Salavert M. Tormo-Mas M.Á. Pemán J. Climate change, animals, and Candida auris: insights into the ecological niche of a new species from a One Health approach. Clin. Microbiol. Infect. 2023 29 7 858 862 10.1016/j.cmi.2023.03.016 36934871
    [Google Scholar]
  4. Puumala E. Fallah S. Robbins N. Cowen L.E. Advancements and challenges in antifungal therapeutic development. Clin. Microbiol. Rev. 2024 37 1 e00142-23 10.1128/cmr.00142‑23 38294218
    [Google Scholar]
  5. Denning D.W. Global incidence and mortality of severe fungal disease. Lancet Infect. Dis. 2024 24 7 e428 e438 10.1016/S1473‑3099(23)00692‑8 38224705
    [Google Scholar]
  6. Allen D. Wilson D. Drew R. Perfect J. Azole antifungals: 35 years of invasive fungal infection management. Expert Rev. Anti Infect. Ther. 2015 13 6 787 798 10.1586/14787210.2015.1032939 25843556
    [Google Scholar]
  7. Biswas M. Shobana J. Jinda P. Sukasem C. Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine. Expert Opin. Drug Metab. Toxicol. 2023 19 3 165 174 10.1080/17425255.2023.2203860 37089014
    [Google Scholar]
  8. Berkow E. Lockhart S. Fluconazole resistance in Candida species: A current perspective. Infect. Drug Resist. 2017 10 237 245 10.2147/IDR.S118892 28814889
    [Google Scholar]
  9. Ramos L.S. Barbosa P.F. Lorentino C.M.A. Lima J.C. Braga A.L. Lima R.V. Giovanini L. Casemiro A.L. Siqueira N.L.M. Costa S.C. Rodrigues C.F. Roudbary M. Branquinha M.H. Santos A.L.S. The multidrug-resistant Candida auris, Candida haemulonii complex and phylogenetic related species: Insights into antifungal resistance mechanisms. Curr. Res. Microb. Sci. 2025 8 100354 10.1016/j.crmicr.2025.100354 39995443
    [Google Scholar]
  10. Pfaller M.A. Diekema D.J. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 2010 36 1 1 53 10.3109/10408410903241444 20088682
    [Google Scholar]
  11. Thompson G.R. III Wiederhold N.P. Isavuconazole: A comprehensive review of spectrum of activity of a new triazole. Mycopathologia 2010 170 5 291 313 10.1007/s11046‑010‑9324‑3 20524153
    [Google Scholar]
  12. Tortorano A.M. Richardson M. Roilides E. van Diepeningen A. Caira M. Munoz P. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive fungal diseases. Clin. Microbiol. Infect. 2014 20 Suppl. 3 1 58
    [Google Scholar]
  13. Arendrup M.C. Patterson T.F. Multidrug-resistant Candida: Epidemiology, molecular mechanisms, and treatment. J. Infect. Dis. 2017 216 Suppl. 3 S445 S451 10.1093/infdis/jix131 28911043
    [Google Scholar]
  14. Chowdhary A. Sharma C. Meis J.F. Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog. 2017 13 5 e1006290 10.1371/journal.ppat.1006290 28542486
    [Google Scholar]
  15. Wiederhold N.P. The antifungal arsenal: Alternative drugs and future targets. Int. J. Antimicrob. Agents 2018 51 3 333 339 10.1016/j.ijantimicag.2017.09.002 28890395
    [Google Scholar]
  16. Rybak J.M. Marx K.R. Nishimoto A.T. Rogers P.D. Azole antifungals: Pharmacology, mechanisms of resistance and therapeutic implications. Drugs 2020 80 799 820
    [Google Scholar]
  17. Czajka K.M. Venkataraman K. Brabant-Kirwan D. Santi S.A. Verschoor C. Appanna V.D. Singh R. Saunders D.P. Tharmalingam S. Molecular mechanisms associated with antifungal resistance in pathogenic Candida species. Cells 2023 12 22 2655 10.3390/cells12222655 37998390
    [Google Scholar]
  18. Dladla M. Gyzenhout M. Marias G. Ghosh S. Azole resistance in Aspergillus fumigatus- Comprehensive review. Arch. Microbiol. 2024 206 7 305 10.1007/s00203‑024‑04026‑z 38878211
    [Google Scholar]
  19. Sen P. Vijay M. Singh S. Hameed S. Vijayaraghvan P. Understanding the environmental drivers of clinical azole resistance in Aspergillus species. Drug Target Insights 2022 16 1 25 35 10.33393/dti.2022.2476 36458152
    [Google Scholar]
  20. Da Silva Ferreira M.E. Colombo A.L. Paulsen I. Ren Q. Wortman J. Huang J. Goldman M.H.S. Goldman G.H. The ergosterol biosynthesis pathway, transporter genes, and azole resistance in Aspergillus fumigatus. Med. Mycol. 2005 43 s1 Suppl. 1 313 319 10.1080/13693780400029114 16110826
    [Google Scholar]
  21. Holmes A.R. Cardno T.S. Strouse J.J. Ivnitski-Steele I. Keniya M.V. Lackovic K. Monk B.C. Sklar L.A. Cannon R.D. Targeting efflux pumps to overcome antifungal drug resistance. Future Med. Chem. 2016 8 12 1485 1501 10.4155/fmc‑2016‑0050 27463566
    [Google Scholar]
  22. Mba I.E. Nweze E.I. Eze E.A. Anyaegbunam Z.K.G. Genome plasticity in Candida albicans: A cutting-edge strategy for evolution, adaptation, and survival. Infect. Genet. Evol. 2022 99 105256 10.1016/j.meegid.2022.105256 35231665
    [Google Scholar]
  23. Selmecki A.M. Dulmage K. Cowen L.E. Anderson J.B. Berman J. Acquisition of aneuploidy provides increased fitness during the evolution of antifungal drug resistance. PLoS Genet. 2009 5 10 e1000705 10.1371/journal.pgen.1000705 19876375
    [Google Scholar]
  24. Lee Y. Robbins N. Cowen L.E. Molecular mechanisms governing antifungal drug resistance. NPJ Antimicrobials and Resistance 2023 1 1 5 10.1038/s44259‑023‑00007‑2 38686214
    [Google Scholar]
  25. Utkalaja B.G. Sahu S.R. Parida S.S. Acharya N. Hsp90-mediated multi-drug resistance in DNA polymerase-defective strains of Candida albicans. J. Fungi (Basel) 2024 10 3 222 10.3390/jof10030222 38535230
    [Google Scholar]
  26. Li C. Tu J. Han G. Liu N. Sheng C. Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans. Eur. J. Med. Chem. 2022 227 113961 10.1016/j.ejmech.2021.113961 34742014
    [Google Scholar]
  27. Santos A.L.S. Galdino A.C.M. Mello T.P. Ramos L.S. Branquinha M.H. Bolognese A.M. Columbano Neto J. Roudbary M. What are the advantages of living in a community? A microbial biofilm perspective! Mem. Inst. Oswaldo Cruz 2018 113 9 e180212 10.1590/0074‑02760180212 30066753
    [Google Scholar]
/content/journals/cmc/10.2174/0109298673413219250826055238
Loading
Azole Antifungals Under Pressure: Therapeutic Challenges and Multifaceted Resistance Mechanisms
Bentham Science Publishers ; https://doi.org/10.2174/0109298673413219250826055238
/content/journals/cmc/10.2174/0109298673413219250826055238
/content/journals/cmc/10.2174/0109298673413219250826055238
Loading

Data & Media loading...


  • Article Type:     Editorial
Keywords: Candida ; chemotherapy ; biofilm ; Aspergillus ; azole antifungals ; Antifungal resistance

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test